ClinicalTrials.gov

History of Changes for Study: NCT02413736
Three Versus Five Years of Adjuvant Imatinib as Treatment of Patients With Operable GIST
Latest version (submitted December 31, 2021) on ClinicalTrials.gov
  • A study version is represented by a row in the table.
  • Select two study versions to compare. One each from columns A and B.
  • Choose either the "Merged" or "Side-by-Side" comparison format to specify how the two study versions are to be displayed. The Side-by-Side format only applies to the Protocol section of the study.
  • Click "Compare" to do the comparison and show the differences.
  • Select a version's Submitted Date link to see a rendering of the study for that version.
  • The yellow A/B choices in the table indicate the study versions currently compared below. A yellow table row indicates the study version currently being viewed.
  • Hover over the "Recruitment Status" to see how the study's recruitment status changed.
  • Study edits or deletions are displayed in red.
  • Study additions are displayed in green.
Study Record Versions
Version A B Submitted Date Changes
1 April 7, 2015 None (earliest Version on record)
2 May 26, 2015 Recruitment Status, Study Status and Contacts/Locations
3 March 4, 2016 Study Status and Eligibility
4 August 9, 2017 Study Status and Outcome Measures
5 August 25, 2018 Study Status and Outcome Measures
6 February 12, 2020 Study Status
7 November 2, 2020 Study Status
8 December 31, 2021 Study Status
Comparison Format:

Scroll up to access the controls

Study NCT02413736
Submitted Date:  April 7, 2015 (v1)

Open or close this module Study Identification
Unique Protocol ID: SSGXXII
Brief Title: Three Versus Five Years of Adjuvant Imatinib as Treatment of Patients With Operable GIST
Official Title: Three Versus Five Years of Adjuvant Imatinib as Treatment of Patients With Operable GIST With a High Risk for Recurrence: A Randomised Phase III Study
Secondary IDs:
Open or close this module Study Status
Record Verification: April 2015
Overall Status: Not yet recruiting
Study Start: May 2015
Primary Completion: May 2028 [Anticipated]
Study Completion: May 2028 [Anticipated]
First Submitted: April 7, 2015
First Submitted that
Met QC Criteria:
April 7, 2015
First Posted: April 10, 2015 [Estimate]
Last Update Submitted that
Met QC Criteria:
April 7, 2015
Last Update Posted: April 10, 2015 [Estimate]
Open or close this module Sponsor/Collaborators
Sponsor: Heikki Joensuu
Responsible Party: Sponsor-Investigator
Investigator: Heikki Joensuu
Official Title: Research Director
Affiliation: Helsinki University Central Hospital
Collaborators: Scandinavian Sarcoma Group
Open or close this module Oversight
U.S. FDA-regulated Drug:
U.S. FDA-regulated Device:
Data Monitoring: No
Open or close this module Study Description
Brief Summary: In this study, patients who have been diagnosed with gastrointestinal stromal tumor (GIST) and have been treated with adjuvant imatinib for 3 years after surgery will be randomly allocated in a 1:1 ratio to receive imatinib (Gleevec) for 2 more years (Arm A) or to stop imatinib (Arm B). The study participants are required to have histologically verified GIST with a high risk of GIST recurrence despite removal of all macroscopic GIST tissue at surgery and 3 years of adjuvant imatinib. The high risk of GIST recurrence is defined as one of the following: gastric GIST with mitotic count >10/50 high power fields (HPFs) of the microscope, non-gastric GIST with mitotic count >5/50 HPFs, or tumor rupture. Study participants allocated to Arm A will receive imatinib 400 mg/day for 24 months after the date of randomization. All study participants will be followed up using blood tests and computerized tomography (or MRI) of the abdomen. The computerized tomography examinations will be performed at 6 month intervals. A total of 300 patients will be entered to the study. The study hypothesis is that adjuvant imatinib given for a total of 5 years may prevent some of the GISTs to recur as compared to patients who receive adjuvant imatinib for 3 years, and there may be a difference in the rate of GIST recurrence between the two groups.
Detailed Description: The study will accrue patients in several countries in the Europe.
Open or close this module Conditions
Conditions: Sarcoma
Keywords:
Open or close this module Study Design
Study Type: Interventional
Primary Purpose: Treatment
Study Phase: Phase 3
Interventional Study Model: Parallel Assignment
Number of Arms: 2
Masking: None (Open Label)
Allocation: Randomized
Enrollment: 300 [Anticipated]
Open or close this module Arms and Interventions
Arms Assigned Interventions
Experimental: Imatinib
Imatinib 400 mg/day for 24 months.
Drug: Imatinib
Imatinib 400 mg/day
Other Names:
  • Gleevec
No Intervention: No imatinib
No further imatinib.
Open or close this module Outcome Measures
Primary Outcome Measures:
1. Recurrence-free survival
[ Time Frame: 5 years ]

Secondary Outcome Measures:
1. Overall survival
[ Time Frame: 5 years ]

2. GIST-specific survival
[ Time Frame: 5 years ]

3. Adverse effects
[ Time Frame: 5 years ]

4. Quality of life
[ Time Frame: 5 years ]

Open or close this module Eligibility
Minimum Age: 18 Years
Maximum Age:
Sex: All
Gender Based:
Accepts Healthy Volunteers: No
Criteria:

Inclusion Criteria:

  • Age ≥ 18 years.
  • Morphological and immunohistological documentation of GIST (immunostaining for KIT and/or DOG-1 positive, or mutation of KIT or PDGFRA present in tumor tissue).
  • Macroscopically complete surgical resection of GIST (either R0 or R1 resection).
  • Mutation analysis of KIT and PDGFR genes has been carried out.
  • A high risk of GIST recurrence; either gastric GIST with mitotic count >10/50 HPFs, or non-gastric GIST with mitotic count >5/50 HPFs, or tumor rupture.
  • Eastern Cooperative Oncology Group performance status ≤ 2.
  • Adequate organ function.
  • Female patients of childbearing potential must have a negative pregnancy test within 14 days before initiation of study drug dosing. Postmenopausal women must have amenorrhea for at least 12 months to be considered of non-childbearing potential. Male and female patients of reproductive potential must agree to employ an effective barrier method of birth control throughout the study and for up to 3 months following discontinuation of study drug.
  • Patient willing to be followed up at the study site regardless of the result of randomization.
  • Patient has provided a written, voluntary informed consent prior to study-specific screening procedures.

Exclusion Criteria:

  • Presence of distant metastases or local recurrence of GIST.
  • Not willing to donate tumor tissue and/or blood samples for the study molecular studies.
  • Presence of a substitution mutation at PDGFRA codon D842 (usually D842V).
  • Administration of adjuvant imatinib longer than for 3 years is planned regardless of the result of randomization, or "life long" imatinib administration is planned.
  • Prior adjuvant (+ neoadjuvant) therapy with imatinib mesylate for at least 35 months has not been completed, or the total duration of prior adjuvant (+ neoadjuvant) imatinib administration exceeds the total duration of 37 months.
  • Neoadjuvant imatinib for a duration that exceeds 9 months.
  • Longer than 4-week break during adjuvant imatinib administration.
  • The dose of imatinib at completion of 3 years of adjuvant imatinib was 200 mg per day or less or greater than 800 mg per day.
  • Patient has received any investigational anti-cancer agents during adjuvant imatinib or between completion of adjuvant imatinib and the date of randomization.
  • Patient has been free of another malignancy for less than 5 years except if the other malignancy is not currently clinically significant nor requiring active intervention, or if the other malignancy is a basal cell skin cancer or a cervical carcinoma in situ. Recent existence of any other malignant disease is not allowed.
  • Patient with Grade III/IV cardiac disease as defined by the New York Heart Association Criteria (i.e., congestive heart failure, myocardial infarction within 6 months of study entry).
  • Female patients who are pregnant or breast-feeding.
  • Severe and/or uncontrolled medical disease (i.e., uncontrolled diabetes, severe chronic renal disease, or active uncontrolled infection).
  • Known diagnosis of human immunodeficiency virus (HIV) infection.
  • Patient with a significant history of non-compliance to medical regimens or with inability to grant reliable informed consent.
Open or close this module Contacts/Locations
Central Contact Person: Heikki Joensuu, MD
Telephone: 094711 Ext. 358
Email: heikki.joensuu@hus.fi
Central Contact Backup: Raija Husa
Telephone: 094711 Ext. 358
Email: raija.husa@hus.fi
Study Officials: Heikki Joensuu
Principal Investigator
Helsinki University Central Hospital
Locations:
Open or close this module IPDSharing
Plan to Share IPD:
Open or close this module References
Citations:
Links:
Available IPD/Information:

Scroll up to access the controls Scroll to the Study top

U.S. National Library of Medicine | U.S. National Institutes of Health | U.S. Department of Health & Human Services